Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
New method at the Danish Medicines Council gives Merck hope of a Danish breakthrough for its sclerosis treatment
German pharmaceutical company Merck has high hopes that a new method of evaluating treatments at the Danish Medicines Council, as well as new data, will pave the way for wider usage of sclerosis drug Mavenclad.
